Production (Stage)
scPharmaceuticals Inc.
SCPH
$3.58
$0.041.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.75M | 12.15M | 10.03M | 8.05M | 6.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.75M | 12.15M | 10.03M | 8.05M | 6.10M |
| Cost of Revenue | 3.47M | 3.97M | 3.31M | 2.30M | 1.79M |
| Gross Profit | 8.28M | 8.19M | 6.72M | 5.75M | 4.32M |
| SG&A Expenses | 21.41M | 21.37M | 21.32M | 17.51M | 17.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.51M | 28.49M | 28.17M | 22.49M | 21.96M |
| Operating Income | -17.76M | -16.34M | -18.15M | -14.43M | -15.86M |
| Income Before Tax | -19.74M | -18.85M | -35.11M | -17.09M | -14.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.74M | -18.85M | -35.11M | -17.09M | -14.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.74M | -18.85M | -35.11M | -17.09M | -14.11M |
| EBIT | -17.76M | -16.34M | -18.15M | -14.43M | -15.86M |
| EBITDA | -17.75M | -16.34M | -18.14M | -14.43M | -15.85M |
| EPS Basic | -0.37 | -0.35 | -0.75 | -0.44 | -0.36 |
| Normalized Basic EPS | -0.23 | -0.22 | -0.49 | -0.27 | -0.23 |
| EPS Diluted | -0.37 | -0.35 | -0.75 | -0.44 | -0.36 |
| Normalized Diluted EPS | -0.23 | -0.22 | -0.49 | -0.27 | -0.23 |
| Average Basic Shares Outstanding | 53.68M | 53.46M | 46.56M | 38.98M | 38.95M |
| Average Diluted Shares Outstanding | 53.68M | 53.46M | 46.56M | 38.98M | 38.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |